A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 35
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DMR
Long Form : deep molecular response
No. Year Title Co-occurring Abbreviation
2019 Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. CML, dPCR, RT-qPCR, TFR, TKI
2019 Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis. CML, TFR, TKI
2019 Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis. CI, TFR, TKI
2019 HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. CML, IM, TKI
2019 Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy. CML, NCCN, TFR, TKI
2019 Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution. CML, MR, TFR, TKI
2019 Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia. CML, CP, EMR, TKI, WBC
2019 Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). CML, ELN, TKI
2019 The impact of tyrosine kinase inhibitors on chronic myeloid leukemia stem cells and the implication on discontinuation. CFC, CML, CML-LSCs, TKIs
10  2019 Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. CML, TFR, TKI
11  2018 Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. CML, HADS, TFR, TKIs
12  2018 BCR-ABL1 transcript levels at 4weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors. EFS, EMR, MMRs, TKIs
13  2018 Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group. CML, MMR
14  2018 Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis. CML, CP, MMR, TKI
15  2018 Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. CML, LGL, NK, TFS, TKI
16  2018 Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. CML, MMR, sDMR, TKIs, UDMR
17  2018 Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. BCR-ABL1IS, CML, MMR, TFR
18  2018 Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial). ---
19  2018 Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. CCyR, CML, MMR
20  2018 Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. DADI, TFR
21  2018 Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase. AEs, CML, CP, MMR
22  2018 Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. AE, CP, DAS, PE
23  2018 The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group. CML-CP, IS, MMR
24  2018 When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. ACA, TFR, TKI
25  2018 [Chronic myeloid leukemia: state-of-the-art management]. CML-CP, TKI
26  2018 [Relationship between BCR-ABLIS and Prognosis and Affecting Factors for Prognosis in CML Patients Treated with TKI for 12 Months]. MMR, TKI
27  2018 [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives]. CML, NK, TFR, TKIs
28  2017 Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. CP-CML, MMR, TKI
29  2017 Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. CI, CML, TFR, TKIs
30  2017 [Analysis of Efficacy and Related Factors of Acquired Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with TKI]. CCyR, CML, MCyR
31  2016 New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment. CML, DADI, TKIs
32  2016 Rationale and protocol of CML study: cognitive and emotional impact of discontinuation of therapy in patients with chronic myeloid leukemia. CML
33  2015 Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. CML, CP, CTL, NK
34  2015 Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. MMR
35  2014 Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment. CML, GTG, TKIs